HYUNDAI FEED Inc (016790) - Cash Flow Conversion Efficiency
Based on the latest financial reports, HYUNDAI FEED Inc (016790) has a cash flow conversion efficiency ratio of 0.014x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.18 Billion ≈ $800.46K USD) by net assets (₩83.53 Billion ≈ $56.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is HYUNDAI FEED Inc worth for the company's overall valuation and market capitalisation.
HYUNDAI FEED Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how HYUNDAI FEED Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
HYUNDAI FEED Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HYUNDAI FEED Inc ranked by their cash flow conversion efficiency. Explore HYUNDAI FEED Inc cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DongWon Development Co.Ltd
KQ:013120
|
-0.017x |
|
Globe Union Industrial Corp
TW:9934
|
0.044x |
|
Loxley Public Company Limited
BK:LOXLEY
|
-0.044x |
|
Unic Technology
TWO:5452
|
-0.104x |
|
Igis Value Plus Reit Co Ltd
KO:334890
|
N/A |
|
Hung -Gu Oil Ltd
KQ:024060
|
0.020x |
|
Kiler Gayrimenkul Yatirim Ortakligi AS
IS:KLGYO
|
0.001x |
|
Cannara Biotech Inc
V:LOVE
|
0.072x |
Annual Cash Flow Conversion Efficiency for HYUNDAI FEED Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of HYUNDAI FEED Inc from 2015 to 2024. View 016790 share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩88.93 Billion ≈ $60.27 Million |
₩860.48 Million ≈ $583.13K |
0.010x | -91.16% |
| 2023-12-31 | ₩-72.23 Billion ≈ $-48.95 Million |
₩-7.91 Billion ≈ $-5.36 Million |
0.110x | +282.63% |
| 2022-12-31 | ₩42.37 Billion ≈ $28.71 Million |
₩-2.54 Billion ≈ $-1.72 Million |
-0.060x | -165.51% |
| 2021-12-31 | ₩57.63 Billion ≈ $39.05 Million |
₩5.27 Billion ≈ $3.57 Million |
0.092x | -59.14% |
| 2020-12-31 | ₩58.97 Billion ≈ $39.96 Million |
₩13.21 Billion ≈ $8.95 Million |
0.224x | +343.11% |
| 2019-12-31 | ₩59.46 Billion ≈ $40.29 Million |
₩-5.48 Billion ≈ $-3.71 Million |
-0.092x | +66.92% |
| 2018-12-31 | ₩56.83 Billion ≈ $38.51 Million |
₩-15.83 Billion ≈ $-10.73 Million |
-0.279x | -262.98% |
| 2017-12-31 | ₩48.74 Billion ≈ $33.03 Million |
₩8.33 Billion ≈ $5.65 Million |
0.171x | -13.94% |
| 2016-12-31 | ₩44.51 Billion ≈ $30.16 Million |
₩8.84 Billion ≈ $5.99 Million |
0.199x | +876.19% |
| 2015-12-31 | ₩42.37 Billion ≈ $28.71 Million |
₩-1.08 Billion ≈ $-734.66K |
-0.026x | -- |
About HYUNDAI FEED Inc
HYUNDAI FEED Inc. engages in the manufacture and sale of formulated feed. Its primary products include poultry and pig feed. The company also engages in the biopharmaceutical business. In addition, it focuses on the development and commercialization of immunotherapies for cancer. Further, the company's lead product includes oregovomab, an immunotherapy for ovarian cancer. Additionally, it is invo… Read more